Simufilam Alzheimer’s Drug Trial Fails, Cassava Sciences Stock Drops
Back in December 2021, after conducting several years of research and initial testing, Cassava Sciences revealed the first phase III trial for their experimental drug, Simufilam, aimed at treating Alzheimer’s disease. By August 2022, more than 400 patients were eagerly waiting to participate. However, just yesterday, after a 52-week clinical trial that included 804 participants, the […]
Simufilam Alzheimer’s Drug Trial Fails, Cassava Sciences Stock Drops Read More »